BRCA2 and breast carcinoma: Rebbeck et al. reported that exon 11 mutations were associated with earlier ages in breast and ovarian cancer diagnosis and mutations conferring NMD or premature termination codon were associated with a later age at breast cancer diagnosis in BRCA1. In BRCA2, the mean age was greater for mutations in OCCR vs. mutations not in OCCR (45.0 vs. 43.9 years, p < 0.001), lower for mutations in BCCR1 vs. mutations not in BCCR1 (42.6 vs. 44.3 years; p = 0.004), and lower for mutations in BCCR2 vs. mutations not in BCCR2 (43.5 vs. 44.3 years, p = 0.04) [50].